Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,712 across all filing types
Latest filing 2026-05-22 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an official announcement of the resolutions passed at the 2025 Annual General Meeting, detailing the voting results for each proposal, the number of shares voted for, against, and abstained, and compliance statements. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-22 Chinese
北京国枫（杭州）律师事务所关于美康生物科技股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 75% confidence The document is a legal opinion letter issued by a law firm on the legality of the procedures, qualifications of participants, and voting results of the company’s 2025 Annual General Meeting. It is not the AGM materials themselves, nor a direct announcement of the meeting resolutions by the company, nor a management or financial report. It is also not an insider dealing, financing update, or proxy solicitation document. No specific category fits this legal opinion format, so it falls under the fallback category for miscellaneous regulatory filings. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-22 Chinese
关于召开2025年年度股东会的提示性公告
AGM Information Classification · 90% confidence The document is a formal convocation notice for the company’s 2025 annual general meeting (AGM), detailing meeting date/time, voting procedures, agenda items, proxy form and related attachments. It serves as preparatory AGM information rather than financial statements or a summary of results. Therefore, it should be classified under AGM Information (AGM-R).
2026-05-19 Chinese
关于公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of medical device registration certificates issued by a regulatory authority (Zhejiang Provincial Drug Administration). It includes details about the certificates, product names, registration numbers, validity periods, and intended uses. The document also discusses the potential impact on company performance and includes a risk warning. The document is short (1244 characters) and does not contain financial statements, management discussion, or detailed financial data. It is an official announcement about a regulatory approval related to product registration, not a financial report or management report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-03-13 Chinese
关于公司及控股子公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of medical device registration certificates by the company and its subsidiary. It includes details about the certificates, their validity, and the expected impact on the company's business. The document is relatively short (1222 characters) and does not contain financial statements, management discussion, or detailed financial data. It is an official announcement about regulatory approvals rather than a financial report or detailed management information. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2026-02-24 Chinese
关于使用部分闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 美康生物科技股份有限公司 regarding the progress of using part of idle raised funds for cash management. It details the amounts invested, types of financial products, expected yields, risk control measures, and approvals by the board. The document is relatively short (3283 characters) and focuses on the update of cash management activities related to idle raised funds, not a full financial report or audit. It is not an annual or interim report, nor an earnings release. It is also not a regulatory certification or legal proceeding. The content fits the category of Capital/Financing Update (CAP), as it provides updates on the company's use of raised funds and cash management activities.
2026-02-06 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.